Alkaline Phosphatase (ALP)

SECTION 2: Hazards identification

1999/45/EC Classification of the substance or mixture Product definition Mixture

2.2 Label elements

None -

Hazard pictograms

None -

Signal word

None -

Hazard statements

None -

Principle Routes of Exposure

- Skin: No adverse effects expected when used as directed. - Eye: No adverse effects expected when used as directed. - Inhalation: No adverse effects expected when used as directed. Ingestion: No adverse effects expected when used as directed. NOTE: All blood products should be treated as potentially infectious. Source material from which this product was derived was found negative when tested in accordance with current FDA required tests. No known test methods can offer assurance that products derived from human blood will not transmit infectious agents. Emergency Phone Number: In emergency situation please contact the National Poison Solidarity Center (Turkey) for information in Turkish ( 114) (24 hours/7 days). Please contact with Archem for information in English +(90) 212 444 0 892 (Turkey) (8 30-18 30/ except Sundays)

2.3 Other hazards

- None -

Results of PBT and vPvB assessment

-

PBT Substances

Not applicable -

vPvB Substances

Not applicable

2.1 Classification of the substance or mixture

Mixture Classification according to Regulation (EC) No 1272/2008 (CLP/GHS): This product has been evaluated per the classification criteria in Regulation (EC) No 1272/2008 (CLP) and the Globally Harmonized System of Classification and Labelling of Chemicals (GHS). This product does not meet the criteria for classification in accordance with either CLP or GHS. - Classification according to Directive 67/548/EEC or Directive 1999/45/EC: - Classification: - Classification system: - The classification is in alignment with current European regulations.